Literature DB >> 16459249

Schizophrenia and diabetes: epidemiological data.

F Rouillon1, F Sorbara.   

Abstract

The association of diabetes mellitus and mental illness, in particular, schizophrenia, has been remarked upon for over a century. Recent epidemiological studies have shown the age- and sex-matched prevalence of diabetes in patients with schizophrenia to be 1.5-2 times those in the general population. This difference is particularly noticeable in younger patients. The explanation for this finding probably resides in both environmental and biological factors. Patients with schizophrenia tend to be sedentary and have a poor diet, which are both known risk factors for diabetes. However, familial studies have indicated a heritable component to the risk of diabetes in patients with schizophrenia. A number of biological mechanisms have been proposed to explain this, including neuroendocrine changes and neurodevelopmental anomalies, but none are entirely satisfactory. In addition, it has been suggested that treatment with antipsychotic medication may potentially increase the risk of diabetes and account for some of the increased prevalence seen in patients with schizophrenia. It has been suggested that different antipsychotic drugs may differ in their ability to facilitate the emergence of poor glycaemic control in patients with schizophrenia. However, the situation is far from clear and more work is required to accurately assess the potential risk associated with different antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16459249     DOI: 10.1016/s0924-9338(05)80189-0

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  11 in total

1.  Emergency department utilization among Medicaid beneficiaries with schizophrenia and diabetes: the consequences of increasing medical complexity.

Authors:  Ruth S Shim; Benjamin G Druss; Shun Zhang; Giyeon Kim; Adesoji Oderinde; Sosunmolu Shoyinka; George Rust
Journal:  Schizophr Res       Date:  2013-12-28       Impact factor: 4.939

Review 2.  [Psychotropic drugs and diabetes].

Authors:  Claudia Ress; Alexander Tschoner; Susanne Kaser; Christoph F Ebenbichler
Journal:  Wien Med Wochenschr       Date:  2011-07-29

3.  Prostate Cancer Related JAZF1 Gene is Associated with Schizophrenia.

Authors:  Ke-Sheng Wang; Lingjun Zuo; Daniel Owusu; Yue Pan; Xingguang Luo
Journal:  J Schizophr Res       Date:  2014-08-01

4.  Predictors of type 2 diabetes in a nationally representative sample of adults with psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; Gerald F Watts; John J McGrath; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

Review 5.  An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists.

Authors:  Aniyizhai Annamalai; Cenk Tek
Journal:  Int J Endocrinol       Date:  2015-03-23       Impact factor: 3.257

6.  Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia.

Authors:  N J M van Beveren; E Schwarz; R Noll; P C Guest; C Meijer; L de Haan; S Bahn
Journal:  Transl Psychiatry       Date:  2014-08-26       Impact factor: 6.222

7.  Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia.

Authors:  Sophie Hackinger; Bram Prins; Vasiliki Mamakou; Eleni Zengini; Eirini Marouli; Luka Brčić; Ioannis Serafetinidis; Klea Lamnissou; Vassilis Kontaxakis; George Dedoussis; Fragiskos Gonidakis; Anastasia Thanopoulou; Nikolaos Tentolouris; Aspasia Tsezou; Eleftheria Zeggini
Journal:  Transl Psychiatry       Date:  2018-11-23       Impact factor: 6.222

8.  Diabetes and cognitive deficits in chronic schizophrenia: a case-control study.

Authors:  Mei Han; Xu-Feng Huang; Da Chun Chen; Meihong Xiu; Thomas R Kosten; Xiang Yang Zhang
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

9.  Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender.

Authors:  Debra L Foley; Andrew Mackinnon; Gerald F Watts; Jonathan E Shaw; Dianna J Magliano; David J Castle; John J McGrath; Anna Waterreus; Vera A Morgan; Cherrie A Galletly
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

10.  Body mass index and blood glucose in psychiatric and general practice populations.

Authors:  Sarah McAvoy; Matthew Cordiner; Jackie Kelly; Laura Chiwanda; Christine Jefferies; Kirsteen Miller; Polash Shajahan
Journal:  BJPsych Bull       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.